These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

704 related items for PubMed ID: 10523895

  • 1. [Benign hypertrophy of the prostate: which treatment, for whom?].
    Schulman C.
    Rev Med Brux; 1999 Sep; 20(4):A212-8. PubMed ID: 10523895
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Durability and cost-effectiveness of transurethral needle ablation of the prostate as an alternative to transurethral resection of the prostate when alpha-adrenergic antagonist therapy fails.
    Rosario DJ, Phillips JT, Chapple CR.
    J Urol; 2007 Mar; 177(3):1047-51; discussion 1051. PubMed ID: 17296409
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms.
    Lowe FC.
    Clin Ther; 2004 Nov; 26(11):1701-13. PubMed ID: 15639685
    [Abstract] [Full Text] [Related]

  • 8. An evaluation of the economic costs and patient-related consequences of treatments for benign prostatic hyperplasia.
    DiSantostefano RL, Biddle AK, Lavelle JP.
    BJU Int; 2006 May; 97(5):1007-16. PubMed ID: 16542339
    [Abstract] [Full Text] [Related]

  • 9. Medical management of benign prostatic hypertrophy.
    Nix JW, Carson CC.
    Can J Urol; 2007 Dec; 14 Suppl 1():53-7. PubMed ID: 18163946
    [Abstract] [Full Text] [Related]

  • 10. [Uroselectivity of alpha-1 antagonism in the treatment of benign prostatic hypertrophy: on the pharmacologic concept of the clinical approach].
    Jolliet P, Bourin M.
    Therapie; 1998 Dec; 53(1):61-6. PubMed ID: 9773101
    [Abstract] [Full Text] [Related]

  • 11. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE.
    Roehrborn CG.
    BJU Int; 2008 Mar; 101 Suppl 3():17-21. PubMed ID: 18307681
    [Abstract] [Full Text] [Related]

  • 12. BPH: costs and treatment outcomes.
    Nickel JC.
    Am J Manag Care; 2006 Apr; 12(5 Suppl):S141-8. PubMed ID: 16613528
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both?
    Carson CC.
    BJU Int; 2006 Apr; 97 Suppl 2():39-43; discussion 44-5. PubMed ID: 16507053
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of the transurethral ethanol ablation of the prostate (TEAP) for symptomatic benign prostatic hyperplasia (BPH): a European multi-center evaluation.
    Grise P, Plante M, Palmer J, Martinez-Sagarra J, Hernandez C, Schettini M, Gonzalez-Martin M, Castiñeiras J, Ballanger P, Teillac P, Rolo F, Baena V, Erdmann J, Mirone V.
    Eur Urol; 2004 Oct; 46(4):496-501; discussion 501-2. PubMed ID: 15363567
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The American Urological Association symptom score in the evaluation of men with lower urinary tract symptoms: at 2 years of followup, does it work?
    Kaplan SA, Olsson CA, Te AE.
    J Urol; 1996 Jun; 155(6):1971-4. PubMed ID: 8618299
    [Abstract] [Full Text] [Related]

  • 18. The impact of medical therapy on surgery for benign prostatic hyperplasia: a study comparing changes in a decade (1992-2002).
    Vela-Navarrete R, Gonzalez-Enguita C, Garcia-Cardoso JV, Manzarbeitia F, Sarasa-Corral JL, Granizo JJ.
    BJU Int; 2005 Nov; 96(7):1045-8. PubMed ID: 16225526
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Impact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: assessment of acute urinary retention and prostate-related surgery.
    Naslund M, Eaddy MT, Hogue SL, Kruep EJ, Shah MB.
    Curr Med Res Opin; 2009 Nov; 25(11):2663-9. PubMed ID: 19757985
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.